Manufacturer of OTC Eye-Drops Forced to Pull Products From Market
The FDA announced today that MBI Distributing, also known as Molecular Biologics, will cease production of all their products due to manufacturing deficiencies and other violations. MBI produces many over-the-counter (OTC) drugs including Oxydrops, Bright Eyes, Bright Eyes II, Clarity Vision for Life, Visitein, and Can-C, as well as several pain relieving drugs.
The deficiencies at MBI's plant resulted in possible unsterile eye-drops and labels with improper or insufficient warnings on OTC drugs.
Read the FDA's news release here.
Post A Comment / Question